Staff Oncologist VCA Veterinary Care Referral Center Albuquerque, New Mexico, United States
Presentation Description / Summary: DIffuse Large B Cell Lymphoma (DLBCL) is the most common form of lymphoma in humans and dogs. While R-CHOP has been the standard of care therapy in humans, as CHOP has been in dogs, the past 5 years have seen notable advances in DLBCL therapy for human patients. Better understanding of the complex molecular subtypes of DLBCL provides a window of opportunity to employ targeted therapies. Human treatment strategies involve refinements in bone marrow transplantation and CAR-T therapy, bispecific antibodies and other immunotherapy approaches. We are making inroads into these strategies for our canine patients. However, for our purposes, this presentation will focus on the rationale of new drug strategies with novel agents that are practical for translation into canine treatment. First-generation small molecular inhibitor drugs such as ibrutinib, bortezomib, lenolidomide, venetoclax, sirolimus, vorinostat and others are potentially accessible to clinical veterinary practice. Incorporating established drugs such as verdinexor and bendamustine into DLBCL protocols can be considered. While speculative, this lecture aims to revisit opportunities for incremental improvement in DLBCL treatment for dogs going forward.
Learning Objectives:
Upon completion, participants will be able to understand the current molecular subtyping of DLBCL in human patients and how this might translate to veterinary patients.
Upon completion, participants will be able to understand how small molecular inhibitors may play a role in DLBCL in dogs.
Upon completion, participants will be able to discuss ongoing immunotherapy research in canine lymphoma treatment.
Upon completion, participants will be able to consider the appliication of real-world trial strategies to move DLBCL therapy forward in veterinary medicine.
